Accéder au contenu
Merck
  • Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) verified in Norway.

Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) verified in Norway.

Antimicrobial agents and chemotherapy (2012-11-28)
Magnus Unemo, Daniel Golparian, Vegard Skogen, Anne Olaug Olsen, Harald Moi, Gaute Syversen, Stig Ove Hjelmevoll
RÉSUMÉ

Gonorrhea may become untreatable, and new treatment options are essential. Verified resistance to spectinomycin is exceedingly rare. However, we describe a high-level spectinomycin-resistant (MIC, >1,024 μg/ml) Neisseria gonorrhoeae strain from Norway with a novel resistance mechanism. The resistance determinant was a deletion of codon 27 (valine) and a K28E alteration in the ribosomal protein 5S. The traditional spectinomycin resistance gene (16S rRNA) was wild type. Despite this exceedingly rare finding, spectinomycin available for treatment of ceftriaxone-resistant urogenital gonorrhea would be very valuable.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Spectinomycine dihydrochloride pentahydrate, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Spectinomycine dihydrochloride pentahydrate, potency: ≥603 μg per mg
Sigma-Aldrich
Spectinomycine dihydrochloride pentahydrate, powder, γ-irradiated
Supelco
Spectinomycin dihydrochloride pentahydrate, VETRANAL®, analytical standard